N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4129-4138

  Sy, Sherwin K B ^a,g   De Kock, Lizanne ^b   Diacon, Andreas H ^b,c   Werely, Cedric J ^d   Xia, Huiming ^e   Rosenkranz, Bernd ^b   Van Der Merwe, Lize ^d,f   Donald, Peter R ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c TASK APPLIED SCIENCE   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^g NEKTAR THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; AMINOSALICYLIC ACID; EFAVIRENZ; N ACYLTRANSFERASE 1; N ACYLTRANSFERASE 2; UNCLASSIFIED DRUG; ARYLAMINE ACETYLTRANSFERASE; DELAYED RELEASE FORMULATION; ISOENZYME; N-ACETYLTRANSFERASE 1; NAT2 PROTEIN, HUMAN; TUBERCULOSTATIC AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BLOATING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG RESISTANT TUBERCULOSIS; DRUG TOLERABILITY; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; OPEN STUDY; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION MAPPING; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ADOLESCENT; ANTIBIOTIC RESISTANCE; BACTERIAL LOAD; DELAYED RELEASE FORMULATION; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; POISSON DISTRIBUTION; SEXUAL DEVELOPMENT; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ACETYLTRANSFERASES; ADOLESCENT; ADULT; ALLELES; AMINOSALICYLIC ACID; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; BACTERIAL LOAD; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; GENOTYPE; HUMANS; ISOENZYMES; MALE; MICROBIAL SENSITIVITY TESTS; POISSON DISTRIBUTION; SEX CHARACTERISTICS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84931275545     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04049-14     Document Type: Article

References (37)

1. Lehmann J. 1946. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet i:15.
2. Crofton J. 1959. Chemotherapy of pulmonary tuberculosis. Br Med J 1:1610-1614. http://dx.doi.org/10.1136/bmj.1.5138.1610.
3. Peloquin CA, Berning SE, Huitt GA, Childs JM, Singleton MD, James GT. 1999. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med 159:932-934. http://dx.doi.org/10.1164/ajrccm.159.3.9807131.
4. Peloquin CA, Henshaw TL, Huitt GA, Berning SE, Nitta AT, James GT. 1994. Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy 14:40-46.
5. Peloquin CA, Zhu M, Adam RD, Singleton MD, Nix DE. 2001. Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. Ann Pharmacother 35:1332-1338. http://dx.doi.org/10.1345/aph.1A088.
6. Liwa AC, Schaaf HS, Rosenkranz B, Seifart HI, Diacon AH, Donald PR. 2013. Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation. J Trop Pediatr 59:90-94. http://dx.doi.org/10.1093/tropej/fms053.
7. Kibleur Y, Brochart H, Schaaf HS, Diacon AH, Donald PR. 2014. Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PASGR) in multidrug-resistant tuberculosis. Clin Drug Invest 34:269-276. http://dx.doi.org/10.1007/s40261-014-0172-7.
8. World Health Organization. 20008. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/challenges/mdr/programmatic-guidelines-for-mdrtb/en/.
9. Heifets LB. 1991. Antituberculosis drugs: antimicrobial activity in vitro, p 13-58. In Heifets LB (ed), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Boca Raton, FL.
10. Mathys V, Wintjens R, Lefevre P, Bertout J, Singhal A, Kiass M, Kurepina N, Wang XM, Mathema B, Baulard A, Kreiswirth BN, Bifani P. 2009. Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 53:2100-2109. http://dx.doi.org/10.1128/AAC.01197-08.
11. Sy SK, Derendorf H. 2014. Pharmacometrics in bacterial infections, p 229-258. In Schmidt S, Derendorf H (ed), Applied pharmacometrics. Springer, New York, NY.
12. Lehmann J. 1969. The role of the metabolism of p-aminosalicylic acid (PAS) in the treatment of tuberculosis. Interaction with the metabolism of isonicotinic acid hydrazide (INH) and the synthesis of cholesterol. Scand J Respir Dis 50:169-185.
13. Motulsky AG, Steinmann L. 1962. Aryl amine acetylation in human red cells. J Clin Invest 41:1387.
14. Vatsis KP, Weber WW. 1993. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 301: 71-76. http://dx.doi.org/10.1006/abbi.1993.1116.
15. Grant D, Vohra P, Avis Y, Ima A. 1992. Detection of a new polymorphism of human arylamine N-acetyltransferase NAT1 using p-aminosalicylic acid as an in vivo probe. J Basic Clin Physiol Pharmacol 3:244.
16. Hughes NC, Janezic SA, McQueen KL, Jewett MA, Castranio T, Bell DA, Grant DM. 1998. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p- aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 8:55-66. http://dx.doi.org/10.1097/00008571-199802000-00008.
17. de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR. 2014. Pharmacokinetics of paraaminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 58:6242-6250. http://dx.doi.org/10.1128/AAC.03073-14.
18. Schaaf HS, Parkin DP, Seifart HI, Werely CJ, Hesseling PB, van Helden PD, Maritz JS, Donald PR. 2005. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 90:614-618. http://dx.doi.org/10.1136/adc.2004.052175.
19. Plan EL. 2014. Modeling and simulation of count data. CPT Pharmacometrics Syst Pharmacol 3:e129. http://dx.doi.org/10.1038/psp.2014.27.
20. Plan EL, Ma G, Nagard M, Jensen J, Karlsson MO. 2011. Transient lower esophageal sphincter relaxation pharmacokinetic-pharmacodynamic modeling: count model and repeated time-to-event model. J Pharmacol Exp Ther 339:878-885. http://dx.doi.org/10.1124/jpet.111.181636.
21. Butcher NJ, Boukouvala S, Sim E, Minchin RF. 2002. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2:30-42. http://dx.doi.org/10.1038/sj.tpj.6500053.
22. Butcher NJ, Ilett KF, Minchin RF. 1998. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations. Pharmacogenetics 8:67-72. http://dx.doi.org/10.1097/00008571-199802000-00009.
23. Loktionov A, Moore W, Spencer SP, Vorster H, Nell T, O'Neill IK, Bingham SA, Cummings JH. 2002. Differences in N-acetylation genotypes between Caucasians and Black South Africans: implications for cancer prevention. Cancer Detect Prev 26:15-22. http://dx.doi.org/10.1016/S0361-090X(02)00010-7.
24. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der Walt BJ, Donald PR, van Jaarsveld PP. 1997. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 155:1717-1722. http://dx.doi.org/10.1164/ajrccm.155.5.9154882.
25. Ahn JE, Plan EL, Karlsson MO, Miller R. 2012. Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment. J Clin Pharmacol 52:880-892. http://dx.doi.org/10.1177/0091270011407193.
26. Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F, Butcher NJ. 2007. Arylamine N-acetyltransferase I. Int J Biochem Cell Biol 39:1999-2005. http://dx.doi.org/10.1016/j.biocel.2006.12.006.
27. Zhangwei X, Jianming X, Qiao M, Xinhua X. 2006. N- Acetyltransferase-1 gene polymorphisms and correlation between genotype and its activity in a central Chinese Han population. Clin Chim Acta 371:85-91. http://dx.doi.org/10.1016/j.cca.2006.02.025.
28. Cascorbi I, Roots I, Brockmoller J. 2001. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1∗10. Cancer Res 61:5051-5056.
29. Butcher NJ, Tetlow NL, Cheung C, Broadhurst GM, Minchin RF. 2007. Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Res 67:85-92. http://dx.doi.org/10.1158/0008-5472.CAN-06-2635.
30. Fox W, Sutherland I. 1956. A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid, and streptomycin plus para-aminosalicylic acid, in pulmonary tuberculosis. Q J Med 25: 221-243.
31. Bang HO, Strandgaard E. 1960. Continued studies on the problems of PAS dosage. Acta Tuberc Scand 39:81-96.
32. Riska N, Tennberg C. 1962. Optimal PAS dosage. Am Rev Respir Dis 86:430-433.
33. Bridge EV, Carr DT. 1958. Clinical use of a single daily dose of paraaminosalicylic acid in association with isoniazid. Am Rev Tuberc 78:749-752.
34. Medical Research Council Investigation. 1952. Prevention of streptomycin resistance by combined chemotherapy. Br Med J 1:1157-1162. http://dx.doi.org/10.1136/bmj.1.4769.1157.
35. Tsukamura M, Noda Y, Yamamoto M, Hayashi M. 1959. Genetic considerations of the mechanisms involved in PAS-resistant tubercle bacilli. Am Rev Tuberc 79:371-373.
36. Singh B, Mitchison DA. 1955. Bactericidal activity of streptomycin and isoniazid in combination with p-aminosalicylic acid against Mycobacterium tuberculosis. J Gen Microbiol 12:76-84. http://dx.doi.org/10.1099/00221287-12-1-76.
37. Jindani A, Aber VR, Edwards EA, Mitchison DA. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121:939-949.